ARCHIVES

Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

New RFAs Released: Kaposi Sarcoma; Rare Tumors; Biochemical Epidemiology; Dietary Questionnaire; Role of Nicotine

August 20, 1982

NCI Cooperative Group, Cancer Center Trials Listed

June 27, 2008

Afinitor Approved for Rare Disorder

November 5, 2010

As Shutdown Nears, House Republicans Press For Deeper Cuts and Repeal of Obamacare

September 13, 2013

FDA To Tighten Up Regulations On Anticancer Drug Combinations, Stop “Permissiveness”

September 3, 1976

ASCO To Include Chernobyl Talk, Educational sessions

May 1, 1987